BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid...

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• The RAS/RAF/MEK/ERK/MAP kinase pathway is crucial for cellular proliferation and tumor growth.
• RAS oncogene mutations are common in various tumors.
• BRAF mutations are implicated in cancers like colorectal and papillary thyroid cancer, particularly in RAS mutation-negative cases.

Purpose of the Study:

• To investigate the prevalence and role of BRAF mutations in solitary cold thyroid adenomas and adenomatous nodules.
• To determine if BRAF mutations contribute to the molecular etiology of RAS mutation-negative cold thyroid nodules.

Main Methods:

• Genomic DNA extraction from nodular and surrounding thyroid tissue.
• Polymerase chain reaction (PCR) amplification of BRAF gene mutational hotspots in exons 11 and 15.
• Screening for mutations using denaturing gradient gel electrophoresis.

Main Results:

• RAS mutations were detected in only one out of 40 cases of cold thyroid adenomas and adenomatous nodules.
• No point mutations were identified in the screened exons (11 and 15) of the BRAF gene.
• BRAF mutations were found to be rare in the studied cohort.

Conclusions:

• BRAF mutations do not appear to be a significant factor in the development of solitary cold adenomas and adenomatous nodules.
• The molecular basis for RAS mutation-negative cold thyroid nodules remains largely unexplained by BRAF mutations.